1-3 of 3
Zhen Shi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors

Yoonha Choi, Neekesh V. Dharia, Tomi Jun, Julie Chang, Stephanie Royer-Joo, Kenneth K. Yau, Zoe J. Assaf, Junko Aimi, Smruthy Sivakumar, Meagan Montesion, Adrian Sacher, Patricia LoRusso, Jayesh Desai, Jennifer L. Schutzman, Zhen Shi, and the GO42144 study group
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (17): 3788–3797.
https://doi.org/10.1158/1078-0432.CCR-24-0255
Published: 03 September 2024
View article titled, Circulating Tumor DNA Dynamics Reveal <em>KRAS G12C</em> Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
Open the PDF for Circulating Tumor DNA Dynamics Reveal <em>KRAS G12C</em> Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer

Zhen Shi, Julia Wulfkuhle, Malgorzata Nowicka, Rosa I. Gallagher, Cristina Saura, Paolo G. Nuciforo, Isabel Calvo, Jay Andersen, José Luis Passos-Coelho, Miguel J. Gil-Gil, Begoña Bermejo, Debra A. Pratt, Eva M. Ciruelos, Patricia Villagrasa, Matthew J. Wongchenko, Emanuel F. Petricoin, Mafalda Oliveira, Steven J. Isakoff
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (5): 993–1003.
https://doi.org/10.1158/1078-0432.CCR-21-2498
Published: 01 March 2022
View article titled, Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer
Open the PDF for Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAFV600-mutated Metastatic Melanoma

Yibing Yan, Matthew J. Wongchenko, Caroline Robert, James Larkin, Paolo A. Ascierto, Brigitte Dréno, Michele Maio, Claus Garbe, Paul B. Chapman, Jeffrey A. Sosman, Zhen Shi, Hartmut Koeppen, Jessie J. Hsu, Ilsung Chang, Ivor Caro, Isabelle Rooney, Grant A. McArthur, Antoni Ribas
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (11): 3239–3246.
https://doi.org/10.1158/1078-0432.CCR-18-0720
Published: 01 June 2019
View article titled, Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with <em>BRAF</em><sup>V600</sup>-mutated Metastatic Melanoma
Open the PDF for Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with <em>BRAF</em><sup>V600</sup>-mutated Metastatic Melanoma in another window
Includes: Supplementary data